期刊文献+

HER2基因扩增和蛋白表达与胃癌临床病理特征和预后的关系 被引量:8

Correlation of HER2 Gene Amplification and Protein Expression with Clinicopathological Characteristics and Prognosis of Gastric Cancer
下载PDF
导出
摘要 背景:曲妥珠单抗在人表皮生长因子受体2(HER2)阳性胃癌分子靶向治疗中的作用已得到确认,研究HER2评分与患者临床结局的关系可确定哪些患者可能从曲妥珠单抗治疗中获益。目的:探讨HER2基因扩增和蛋白表达与胃癌临床病理特征和预后的关系。方法:应用美国食品药品管理局(FDA)认证的检测试剂盒和Hofmann等报道的共识小组推荐胃癌HER2评分系统,采用荧光原位杂交(FISH)和免疫组化方法(IHC)检测177例胃癌组织的HER2基因扩增和蛋白表达。比较不同临床病理特征胃癌亚组间HER2阳性率的差异,以Kaplan.Meier生存曲线分析HER2与预后的关系。结果:177例胃癌组织中31例(17.5%)HER2阳性,肠型胃癌阳性率显著高于弥漫型/混合型胃癌(28.1%对12.5%,P=0.0109),分化较好的胃癌阳性率显著高于分化较差的胃癌(37.0%对10.7%.P<0.0001)。HER2与性别、年龄、肿瘤部位和TNM分期无关。HER2阳性与阴性者总体生存率无明显差异,但在分化较好的胃癌中,HER2阳性者预后差于HER2阴性者(P=0.0084)。结论:肠型胃癌和分化较好的胃癌是曲妥珠单抗治疗的主要候选人群。HER2尚不能作为独立指标判断胃癌预后。 Background: The efficacy of trastuzumab for treating human epidermal growth factor receptor 2 (HER2)-positive gastric cancer (GC) has been confirmed by phase HI clinical trial. Investigation on correlation of HER2 score with clinical outcome will be helpful for determining which patient might be benefit from trastuzumab therapy. Aims: To study the correlation of HER2 gene amplification and protein expression with clinicopathological characteristics and prognosis of GC. Methods: One hundred and seventy-seven GC specimens were collected. HER2 gene amplification and protein expression were detem^ined by using the Food and Drug Administration (FDA)-approved kits for fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC), and were scored according to the consensus panel recommendations on HER2 scoring for GC. The difference in HER2 positivity rate among GC with different clinicopathological characteristics was analyzed, and the correlation between HER2 and prognosis was estimated by Kaplan-Meier survival curve. Results: Thirty-one cases of GC (17.5%) were positive for HER2. The positivity rates in intestinal type GC and well-differentiated GC were higher than those in diffuse/mixed type GC and poorly-differentiated GC, respectively (28.1% vs. 12.5%, P=O.O109, 37.0% vs. 10.7%, P〈O.0001), but were not correlated with gender, age, tumor location and TNM stage. The overall survival was not significantly different between HER2-positive and HER2-negative GC, but in well- differentiated cases, the survival of HER2-positive GC was worse than that of HER2-negative GC (P =0.0084). Conclusions: Patients with intestinal type GC and well-differentiated GC may be the potential responders to trastuzumab therapy. HER2 can not yet be served as an independent predictor for prognosis of GC.
出处 《胃肠病学》 2011年第5期267-271,共5页 Chinese Journal of Gastroenterology
关键词 胃肿瘤 人表皮生长因子受体2 预后 原位杂交 荧光 免疫组织化学 Stomach Neoplasms Human Epidermal Growth Factor Receptor 2 Prognosis In Situ Hybridization, Fluorescence Immunohistochemistry
  • 引文网络
  • 相关文献

参考文献13

  • 1Van Cutsem E, Kang Y, Chung H, et al. Efficacy results from the ToGA trial: A phase Ⅲ study of trastuzumab added to standard chemotherapy (CT) in first-line human epidermal growth factor receptor 2 (HER2)-positive advanced gastric eaneer (GC). 2009 ASCO Annual Meeting Proeeedings (Post-Meeting Edition). J Clin Oncol, 2009, 27 (18S): LBA4509.
  • 2Hofmann M, Stoss O, Shi D, et al. Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology, 2008, 52 (7): 797-805.
  • 3Fukushige S, Matsubara K, Yoshida M, et al. Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line. Mol Cell Biol, 1986, 6 (3): 955-958.
  • 4Sakai K, Mori S, Kawamoto T, et al. Expression of epidermal growth factor receptors on normal human gastric epithelia and gastric careinomas. J Natl Cancer Inst, 1986, 77 (5): 1047-1052.
  • 5Jorgensen JT. Targeted HER2 treatment in advanced gastric cancer. Oncology, 2010, 78 (1): 26-33.
  • 6Wolff AC, Hammond ME, Schwartz JN, et al; American Society of Clinical Oncology/College of American Pathologists. American Society of Clinical Oncology/ College of American Pathologists guideline recommen- dations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med, 2007, 131 (1): 18-43.
  • 7Marx AH, Tharun L, Muth J, et al. HER-2 amplification is highly homogenous in gastric cancer. Hum Pathol, 2009, 40 (6): 769-777.
  • 8Yu GZ, Chen Y, Wang JJ. Overexpression of Grb2/HER2 signaling in Chinese gastric cancer:, their relationship with clinicopathological parameters and prognostic significance. J Cancer Res Clin Oncol, 2009, 135 (10): 1331-1339.
  • 9Bang Y, Chung H, Sawaki A, et al. HER2-positivity rates in advanced gastric cancer (GC): Results from a large international phase Ⅲ trial. 2008 ASCO Annual Meeting. J Clin Oncol, 2008, 26 (20S): abstr 4526.
  • 10Zhang XL, Yang YS, Xu DP, et al. Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. World J Surg, 2009, 33 (10): 2112-2118.

同被引文献57

  • 1汪步海,钱伟,朱良如,侯晓华.COX-2基因沉默对人胃癌细胞系SGC-7901裸鼠成瘤的影响[J].现代医学,2007,35(5):351-355. 被引量:3
  • 2Qiao Qiao CHEN,Xiao Ying CHEN,Yun Yun JIANG,Jing LIU.Identification of novel nuclear localization signal within the ErbB-2 protein[J].Cell Research,2005,15(7):504-510. 被引量:9
  • 3Cunningham D,Allum WH,Stenning SP,菅鑫妍.手术期间化学疗法与单独手术治疗可切除的胃食管癌疗效比较[J].中国处方药,2006,5(8):59-60. 被引量:434
  • 4李国秀,李建科.纳米技术在食品领域中应用[J].粮食与油脂,2007,20(8):13-14. 被引量:6
  • 5Grabsch H,et al.HER-2 expression in gastric cancer:Rare,hetero-geneous and of no prognostic value-conclusions from 924 cases of two in-dependent series.Cell Oncol,2010,32(1-2):57-65.
  • 6Dohadwala M,et al.Non-small cell lung cancer cyclooxygenase-2dependent invasion is mediated by CD44[J].J Biol Chem,2011,276(24):20809-20812.
  • 7Liao X,fet al.Effects of propranolol in combination with radiationon apoptosis and survival of gastric cancer cells in vitro[J].Radiat Oncol,2010,26(5):98.
  • 8Gou HF,et al.Expression of COX-2 and VEGF-C in gastriccancer:correlation with lymphangiogenesis and prognostic implications[J].Exp Clin Cancer Res,2011,30(1):14.
  • 9Achen MG,Stacker SA.Molecular control of lymphatic metastasia[J].Ann N Y Acad Sci,2008,1131:225-234.
  • 10Yung-Jue Bang,Eric Van Cutsem,Andrea Feyereislova,Hyun C Chung,Lin Shen,Akira Sawaki,Florian Lordick,Atsushi Ohtsu,Yasushi Omuro,Taroh Satoh,Giuseppe Aprile,Evgeny Kulikov,Julie Hill,Michaela Lehle,Josef Rüschoff,Yoon-Koo Kang.Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial[J]. The Lancet . 2010 (9742)

引证文献8

二级引证文献28

相关主题

;
使用帮助 返回顶部